https://www.selleckchem.com/pr....oducts/ipilimumab.ht
patients with advanced NSCLC. This treatment mode offers additional advantages over supportive care alone. Female patients have lower progression risk and better prognoses than male patients, younger patients have higher progression risk but better long-term prognoses than the elderlys, and patients with lower performance status scores are at lower risk for progression and have better prognoses. Comprehensive CM treatments could significantly reduce progression risk, improve prognosis, and prolong survival time for patients with adva
Like
Comment
Share
